ClinicalTrials.gg
Not yet recruitingNCT07171086AIM-ETHUpdated Sep 12, 2025

AI-POCUS for Maternal and Neonatal Health in Ethiopia

A Phase 4 interventional study of AI-POCUS (BabyChecker, Delft Imaging) and AI-POCUS (Edan, China) in Pregnancy, Pregnancy Complications and Preterm Birth, sponsored by Tsinghua University. Not yet recruiting at 1 site in Ethiopia. Open to female participants aged 15 Years to 49 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-12.

Sponsored by Tsinghua University · Phase 4, Interventional, and Screening

How we know

From the registry’s dates

  • Primary completion was expected by Mar 2026, 7 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
1,059
Allocation
Randomized
Ages
15 Years to 49 Years
Sex
Female
01

Study summary

Maternal and neonatal health remains one of the most pressing global health challenges, particularly in low- and middle-income countries (LMICs). Ethiopia continues to face a high burden, with maternal mortality estimated at 195 per 100,000 live births, neonatal mortality at 27 per 1,000 live births, and perinatal mortality rates ranging from 37‰ to 124‰ depending on the level of care. These outcomes remain substantially higher than the targets set under the United Nations Sustainable Development Goals (SDGs) for 2030.

The World Health Organization (WHO) recommends that all pregnant women receive at least one ultrasound scan before 24 weeks of gestation, yet nearly two-thirds of women worldwide-especially in LMICs-lack access to this service. Barriers include high costs of ultrasound machines, limited technical expertise, and shortages of skilled sonographers in rural primary care.

Artificial Intelligence-driven Point-of-Care Ultrasound (AI-POCUS) represents a promising innovation to expand prenatal imaging in resource-constrained settings by equipping frontline health workers with AI-supported diagnostic capabilities. This study, conducted under the Tsinghua University BRIGHT (Bringing Research to Impact for Global Health at Tsinghua) program, will evaluate the clinical effectiveness, feasibility, cost, and scalability of AI-POCUS in rural Ethiopia. A three-arm cluster randomized controlled trial will compare two AI-enabled ultrasound technologies-BabyChecker (Netherlands) and a China-developed AI-POCUS device-against standard antenatal care without ultrasound. Findings will generate robust clinical and policy-relevant evidence to guide the sustainable implementation of AI-enabled maternal health interventions in sub-Saharan Africa.

Read the detailed description

Maternal and neonatal morbidity and mortality remain unacceptably high in sub-Saharan Africa and continue to impede progress toward global health targets. In Ethiopia, recent estimates show maternal mortality at 195 per 100,000 live births and neonatal mortality at 27 per 1,000 live births. Perinatal mortality is also elevated, ranging between 66‰ and 124‰ in hospital-based settings and 37‰ to 52‰ in community-level health facilities. These figures surpass the Sustainable Development Goal (SDG) thresholds for 2030, underscoring the urgent need for innovative, scalable solutions.

Ultrasound imaging is a cornerstone of modern antenatal care. The WHO recommends at least one ultrasound before 24 weeks' gestation to assess gestational age, detect multiple pregnancies, identify fetal anomalies, and diagnose high-risk conditions such as preeclampsia, placenta previa, or growth restriction. However, nearly two-thirds of pregnant women worldwide still lack access to this basic diagnostic tool. In low-resource environments, the barriers include limited infrastructure, high equipment costs, technical complexity, and the scarcity of trained professionals capable of performing and interpreting scans. As a result, potentially preventable maternal and neonatal deaths remain common.

Artificial Intelligence-driven Point-of-Care Ultrasound (AI-POCUS) introduces a transformative opportunity to address these gaps. POCUS devices embedded with AI algorithms can guide non-specialist health workers in image acquisition and interpretation, reducing reliance on highly trained personnel and lowering barriers to integration within primary care. Such innovations may strengthen early detection of pregnancy complications, enable timely referral to higher-level care, and ultimately improve maternal and neonatal survival.

This study is embedded within the Bringing Research to Impact for Global Health at Tsinghua (BRIGHT) initiative. It will use a three-arm cluster randomized controlled trial (C-RCT) design to evaluate and compare: (1) BabyChecker, a portable AI-enabled ultrasound developed in the Netherlands, (2) A China-developed AI-POCUS device, and (3) Standard antenatal care (ANC) without ultrasound, reflecting current practice in many rural Ethiopian communities.

The study population will include pregnant women receiving antenatal care in rural Ethiopia, as well as primary health care providers delivering these services. Data will be collected at both the patient and facility level to capture maternal and neonatal health outcomes, health service utilization, and system-level performance indicators.

Evaluation will follow a multi-dimensional framework, addressing:

  1. Clinical effectiveness: improved detection of high-risk pregnancies, reduced maternal and neonatal complications, and mortality.
  2. Implementation feasibility and acceptability: user experience among health workers and pregnant women, integration into routine workflows, and perceived trust in AI-assisted care.
  3. Economic evaluation: cost and cost-effectiveness of AI-POCUS compared to standard ANC, including resource utilization, referral patterns, and potential savings from earlier detection.
  4. Scalability and policy relevance: analysis of barriers and enablers for broader adoption in Ethiopia and similar LMIC contexts, with direct input from policymakers and health system stakeholders.

The study aims to provide rigorous clinical evidence and practical implementation guidance on how AI-POCUS technologies can be sustainably scaled in resource-constrained settings. Findings are expected to inform national health policies, guide investment decisions, and offer a replicable model for expanding maternal health technologies across sub-Saharan Africa and other LMICs.

02

Conditions studied

  • Pregnancy
  • Pregnancy Complications
  • Preterm Birth
  • Fetal Growth Restriction
  • Stillbirth and Fetal Death
  • Pregnancy Abnormal

Keywords

  • Artificial Intelligence
  • Point-of-Care Ultrasound (POCUS)
  • Maternal and Neonatal Health
  • Cluster Randomized Controlled Trial
  • Sub-Saharan Africa
  • Rural Centers
03

In context

Pregnancy Complications

411 studies on the registry are indexed under Pregnancy Complications; 111 are open to participants now.

This study's planned enrollment of 1,059 is above the median of 144 across 205 interventional studies indexed under Pregnancy Complications.

Browse Pregnancy Complications studies →

Lead sponsor

Tsinghua University is the lead sponsor of 28 studies on the registry; 15 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
15 Years to 49 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged 15-49 years;
  2. Gestational age less than 24 weeks at the first ANC visit;
  3. No history of severe pregnancy complications (e.g., placenta previa, preeclampsia, etc.);
  4. Signed and agreed to participate in the study.

Exclusion criteria

Exclusion Criteria:

  1. Pregnant women with cognitive impairments or unable to communicate effectively;
  2. Failure to complete antenatal care within the specified timeframe;
  3. Incomplete or unavailable records of antenatal care and delivery.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Primary purpose
Screening
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
1,059 participants (estimated)

Study arms

  • No intervention
    Standard Care Control

    Participants in this arm will receive routine antenatal care (ANC) according to Ethiopian national guidelines, without the use of AI-POCUS devices. All examinations, screenings, and referrals will be conducted through standard clinical practice. This group serves as the baseline comparator for evaluating the added impact of AI-POCUS technology.

  • Experimental
    BabyChecker (Delft Imaging, Netherlands)

    Health centers in this arm will be equipped with the BabyChecker system developed by Delft Imaging (Netherlands). The portable device integrates fetal position, amniotic fluid volume, and biparietal diameter measurements, and provides diagnostic suggestions and risk alerts. After brief training, primary healthcare workers will independently perform antenatal examinations, screen for obstetric complications, and make referral decisions.

    Device: AI-POCUS (BabyChecker, Delft Imaging)

  • Experimental
    AI-POCUS (Edan, China)

    This arm will use the AI-POCUS device developed by Edan (China), designed to analyze blind ultrasound sweeps and automatically extract fetal diagnostic parameters. The system supports the early detection of maternal and fetal risks and assists in clinical decision-making.

    Device: AI-POCUS (Edan, China)

Interventions

  • DeviceAI-POCUS (BabyChecker, Delft Imaging)

    A portable AI-driven ultrasound system developed by Delft Imaging (Netherlands). The device integrates fetal position, amniotic fluid volume, and biparietal diameter measurements, with built-in diagnostic suggestions and risk alerts. Primary healthcare workers, after brief training, use it for antenatal screening, complication detection, and referral decision-making.

  • DeviceAI-POCUS (Edan, China)

    An AI-POCUS device developed by Edan (China), capable of analyzing blind ultrasound sweeps to extract fetal diagnostic parameters and assist in early risk identification. It supports clinical decision-making for antenatal care.

06

What researchers measure

Primary outcomes

  1. Maternal Mortality Ratio

    Maternal deaths per 100,000 live births, defined as deaths occurring during pregnancy or within 42 days postpartum due to pregnancy-related causes.

    Time frame: Baseline through 42 days postpartum

  2. Stillbirth Rate / Perinatal Mortality Rate

    Stillbirths (≥28 weeks gestation) per 1,000 total births, and perinatal mortality including stillbirths and neonatal deaths within the first 7 days of life.

    Time frame: Delivery through 7 days postpartum

  3. Early Neonatal Mortality Rate

    Neonatal deaths within the first 7 days of life per 1,000 live births.

    Time frame: Birth through 7 days postpartum

  4. Preterm Birth Rate

    Proportion of births before 37 completed weeks of gestation, subdivided into extremely preterm (\<32 weeks), very preterm (32-33 weeks), and late preterm (34-36 weeks).

    Time frame: At delivery

  5. Maternal and Neonatal Referral Rate

    Proportion of mothers or newborns referred to higher-level hospitals due to severe complications.

    Time frame: Antenatal period through 42 days postpartum

  6. Congenital Anomaly Rate

    Proportion of infants with major structural anomalies detected by prenatal ultrasound or confirmed postnatally (e.g., neural tube defects, limb malformations, cleft lip/palate).

    Time frame: Antenatal period through delivery

Secondary outcomes

  1. Completion of ≥4/8 Antenatal Care (ANC) Visits

    Proportion of pregnant women who completed at least 4 of 8 ANC visits, respectively, during pregnancy, according to WHO recommendations.

    Time frame: Pregnancy through delivery

  2. High-Risk Pregnancy Detection Rate

    Proportion of pregnant women identified as high-risk (e.g., placenta previa, malpresentation) by AI-POCUS or conventional ultrasound, divided by total enrolled women.

    Time frame: Pregnancy through delivery

  3. High-Risk Pregnancy Follow-Up Completion Rate

    Among women identified as high-risk, proportion who completed at least 1 or 2 follow-up ANC visits.

    Time frame: Pregnancy through delivery

  4. Referral Completion Rate After Screening

    Proportion of women meeting high-risk pregnancy criteria who successfully completed referral to a higher-level hospital.

    Time frame: Pregnancy through delivery

07

Study locations

1 site
  • Hakim Gizaw Hospital
    Debre Berhan, Amhara 1000, Ethiopia
08

References and documents

Individual participant data

Plan to share: Undecided — Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Sep 2025; primary completion for Mar 2026, 6 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 5, 2025
First posted
Sep 12, 2025
StartEst.
Sep 30, 2025
Primary completionEst.
Mar 31, 2026
CompletionEst.
Aug 31, 2026
Last update
Sep 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07171086
Lead sponsor
Tsinghua University
Collaborators
Debre Berhan University
Responsible party
Yuxuan LI (Doctoral Candidate, Tsinghua University) — Principal investigator
First posted
Sep 12, 2025
Start date
Sep 30, 2025 (estimated)
Primary completion
Mar 31, 2026 (estimated)
Completion
Aug 31, 2026 (estimated)
Last update
Sep 12, 2025

Study contacts

Yuxuan LI, Doctoral Candidate
Contact
li-yx23@mails.tsinghua.edu.cn
+86-18813076657
Kun TANG, Associate Professor
study chair · Tsinghua University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion